GA-68 DOTA-TOC of Somatostatin Positive Malignancies

NCT02177773 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

300

Enrollment

OTHER

Sponsor class

Stopped FDA approved agent for this indication during enrollment

Conditions

Neuroendocrine Tumor
Paraganglioma
Carcinoid Tumors
Neuroblastoma

Interventions

PROCEDURE: Computed Tomography (CT)
DRUG: Gallium Ga 68-Edotreotide
PROCEDURE: Magnetic Resonance Imaging (MRI)
PROCEDURE: Positron Emission Tomography (PET)

Sponsor

University of California, San Francisco

Collaborators

[object Object]